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The Oncogene ATF3 Is Potentiated by Cyclosporine A
and Ultraviolet Light A
Piotr J. Dziunycz1, Karine Lefort2, Xunwei Wu3, Sandra N. Freiberger1, Johannes Neu1, Nadia Djerbi1,
Guergana Iotzowa-Weiss1, Lars E. French1, Gian-Paolo Dotto2,3 and Gu¨nther F.L. Hofbauer1
Cutaneous squamous cell carcinoma (SCC) represents the most important cutaneous complication following
organ transplantation. It develops mostly on sun-exposed areas. A recent study showed the role of activating
transcription factor 3 (ATF3) in SCC development following treatment with calcineurin inhibitors. It has been
reported that ATF3, which may act as an oncogene, is under negative calcineurin/nuclear factor of activated
T cells (NFAT) control and is upregulated by calcineurin inhibitors. Still, these findings do not fully explain the
preferential appearance of SCC on chronically sun-damaged skin. We analyzed the influence of UV radiation on
ATF3 expression and its potential role in SCC development. We found that ATF3 is a specifically induced AP1
member in SCC of transplanted patients. Its expression was strongly potentiated by combination of cyclosporine
A and UVA treatment. UVA induced ATF3 expression through reactive oxygen species-mediated nuclear factor
erythroid 2–related factor 2 (NRF2) activation independently of calcineurin/NFAT inhibition. Activated NRF2
directly binds to ATF3 promoter, thus inducing its expression. These results demonstrate two mechanisms that
independently induce and, when combined together, potentiate the expression of ATF3, which may then force
SCC development. Taking into account the previously defined role of ATF3 in the SCC development, these
findings may provide an explanation and a mechanism for the frequently observed burden on SCCs on sun-
exposed areas of the skin in organ transplant recipients treated by calcineurin inhibitors.
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INTRODUCTION
Squamous cell carcinoma (SCC) of the skin is one of the most
common cancers at large and the second most common
cancer of the skin. Predilection sites for SCC are the sun-
exposed areas of the skin, such as the face, the balding head,
the dorsum of the hands, and the lower arms. This clinical
distribution highlights chronic low-level UV light exposure as
a major factor for SCC formation.
Following organ transplantation, SCC emerges as the most
common cancer: SCC occurs 65- to 250-fold more frequently
in organ transplant recipients (OTRs) than in the general
population (Kempf et al., 2012). As a result, 20–75% of OTRs
are affected by at least one SCC within 20 years of transplan-
tation (Hofbauer et al., 2010). Immunosuppressive drugs drive
this greatly increased formation of SCC in OTR. Azathioprine
photosensitizes cells to UVA and shows clinically relevant
effects at the molecular level on keratinocytes (Hofbauer et al.,
2012). Calcineurin inhibition is the cornerstone of most
immunosuppressive regimes. A number of studies have
shown that deregulation of calcineurin-NFAT signaling has
an important role in tumorigenesis (Dotto, 2011). The
most commonly used inhibitor of calcineurin, cyclosporine
A (CsA), directly induces tumor growth in murine models (Wu
et al., 2010) and increases the secretion of transforming
growth factor-b and vascular endothelial growth factor
conducive to SCC formation (Hofbauer, 2010). Although
cyclosporine promotes SCC formation, a switch to mamma-
lian target of rapamycin inhibitors such as rapamycin reduces
SCC formation in OTR (Euvrard et al., 2012). Recently,
calcineurin inhibition was recognized to selectively induce
the expression of activating transcription factor 3 (ATF3)—a
member of the ‘enlarged’ AP-1 family (Wu et al., 2010). ATF3
downregulates p53 expression by direct negative regulation of
p53 messenger RNA (mRNA) expression and thus increases
SCC formation in vitro in a mouse model and in human SCC
(Wu et al., 2010).
Although immunosuppressive drugs have a major role
in SCC formation in OTR, these patients still show a pre-
dilection for skin areas with chronic sun damage (Lindelof
et al., 2005). We therefore speculated that a synergistic
effect between UV light and immunosuppression causes
the predilection of SCC in OTR for chronically sun-exposed
skin.
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Here we found that UVA induces ATF3 expression by
induction of nuclear factor erythroid 2–related factor 2 (NRF2)
binding to the ATF3 promoter. The Nrf2-Keap1 (Kelch-like
erythroid cell–derived protein with CNC homology (ECH)–
associated protein 1) signaling pathway is one of the most
important cell defense and survival pathways. Nrf2 can
protect cells and tissues from a variety of toxicants and
carcinogens by increasing the expression of a number of
cytoprotective genes (Jaramillo and Zhang, 2013). Just as Nrf2
protects normal cells, studies have shown that Nrf2 may also
protect cancer cells from chemotherapeutic agents and
facilitate cancer progression. Nrf2 is aberrantly accumulated
in many types of cancer, and its expression is associated with
a poor prognosis in patients (Jaramillo and Zhang, 2013).
Our experiments reveal that UVA and cyclosporin potenti-
ate expression of the transcription factor ATF3, suggesting an
explanation for the clinically observed increase of SCC on the
sun-damaged skin of OTRs.
RESULTS
ATF3 is a selectively upregulated AP1 family member in SCC of
immunosuppressed patients
The real-time PCR analysis performed on SCCs from immu-
nocompetent and immunosuppressed patients showed signifi-
cant and specific upregulation of ATF3 expression in the OTR
group (Figure 1a). The samples were analyzed for the expres-
sion of several members of the ‘enlarged’ AP-1 family;
however, there was no increase in mRNA expression for
ATF2, ATF4, c-Jun, or c-Fos. As ATF3 is known to function
as a transcription factor (Thompson et al., 2009), an open
question was whether the observed increase in ATF3 mRNA
level affects the expression of downstream targets of ATF3.
Several putative ATF3 downstream genes have been identified,
among them GADD153 (Wolfgang et al., 1997). Interestingly,
GADD153 mRNA was also increased in the OTR group in
parallel to the increase of ATF3 mRNA expression (Figure 1b).
We then aimed to identify putative ATF3-regulated genes
in normal human keratinocytes. A complementary DNA
microarray analysis of keratinocytes overexpressing ATF3
and keratinocytes with downregulated expression of ATF3
suggested four putative ATF3 downstream targets (see
Supplementary Table S1 online). Among them, Vanin-1 and
potassium intermediate/small conductance calcium-activated
channel, subfamily N, member 4 (KCNN4) were upregulated
in the ATF3-overexpressing cells and downregulated in the
siATF3-treated cells (Supplementary Table S1 online). Real-
time PCR expression analysis of Vanin-1 and KCNN4 showed
a clear upregulation of mRNA expression for these two genes
in OTRs (Figure 1c) in line with the increased ATF3 mRNA
expression observed in the same samples.
ATF3 expression is potentiated by CsA and UVA treatment
Consistent with previously published findings (Wu et al.,
2010), CsA-treated cells showed increased ATF3 mRNA and
protein levels in a dose-dependent manner (Figure 2a and b).
In the study by Wu et al., it was also demonstrated that such
CsA-driven induction of ATF3 has a major influence on SCC
development. As UV radiation is one of the most important
risk factors for SCC development, we exposed the primary
human keratinocytes to low doses of UVA and UVB irradia-
tion. Interestingly, UVA treatment significantly elevated
ATF3 mRNA and protein expression (Figure 2c and d),
whereas UVB had only moderate effects on ATF3 mRNA
levels (Supplementary Figure S1 online). When low levels of
CsA and UVA treatment of cultured primary human keratino-
cytes were combined, the upregulation of ATF3 expression
was potentiated: the UVA- and CsA-treated cells expressed
ATF3 at higher mRNA and protein levels than did keratino-
cytes treated with UVA or CsA alone (Figure 2e and f). These
findings were next verified in a model of organ culture of
normal human skin (Figure 2g and h). CsA treatment induced
ATF3 expression in the epidermis. When normal skin was
irradiated with low doses of UVA, only a slight induction of
ATF3 was observed at the protein level. However, when skin
was pretreated with CsA and then exposed to UVA irradiation,
the combined treatment strongly induced ATF3 expression at
both the mRNA and protein level in the epidermis. This
synergistic impact of UVA and CsA on gene expression was
very potent and specific for ATF3 alone. Expression of other
AP-1 family members was not influenced by the combined
UVA and CsA treatment (see Supplementary Data online).
UVA-mediated induction of ATF3 expression requires reactive
oxygen species (ROS) formation and NRF2 activation
UVA influences the cellular processes mostly by the induction
of stress, and particularly by the formation of ROS. Primary
human keratinocytes exposed to UVA radiation strongly
induce the formation of ROS. This, however, can be decreased
by pretreatment of the cells with b-carotene and to a lesser
extent with a-tocopherol, both of which serve as ROS scaven-
gers (Figure 3a). Interestingly, once cells were pretreated with
either of these two scavengers and then exposed to UVA
irradiation, UV light was less potent in its induction of ATF3
expression (Figure 3b). The inhibition of ATF3 expression
correlated with the strength of the compound as a ROS
scavenger. b-Carotene, which is more potent in the reduction
of ROS formation (Figure 3a), also strongly inhibited ATF3
formation after UVA irradiation (Figure 3b). This effect
was less pronounced in the case of pretreatment with
a-tocopherol, which is also reported to be a less potent ROS
scavenger than b-carotene.
These results were verified in skin culture. Epidermis of the
normal skin exposed to UVA at 50 J cm2 increased its expres-
sion of ATF3. However, ATF3 induction was strongly reduced
by pretreatment with b-carotene (Figure 3c). This effect was
also confirmed at the protein level (Figure 3d). The cell injury
caused by UVA irradiation is known to induce the expression
of genes encoding antioxidant and/or phase 2 detoxifying
enzymes (Gruber et al., 2010). The main transcription factor
involved in this response is nuclear factor erythroid 2–related
factor 2 (Nrf2; Marrot et al., 2008). In our study, UVA
irradiation induced the protein expression of NRF2 in the
epidermis, and this effect could be counteracted by an
antioxidative treatment with b-carotene (Figure 3d).
Previous reports suggested a close relation between NRF2
and ATF3 expression in other cells such as inflammatory cells
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(Hoetzenecker et al., 2012). To verify whether UV induces
ATF3 expression through NRF2 activation, primary human
keratinocytes were treated with NRF2-specific small interfer-
ing RNA (siRNA). Cells treated with control siRNA and
exposed to UVA induced the expression of both NRF2 and
ATF3. However, the UVA-mediated ATF3 induction was
inhibited in NRF2 knockdown keratinocytes (Figure 3e). To
verify these results, cells were treated with tert-butylhydroqui-
none, which is a known NRF2 stabilizer (Khodagholi and Tusi,
2011). The NRF2 stabilization by tert-butylhydroquinone
increased the expression of ATF3. This, however, was
abolished in NRF2 knockdown cells (Figure 3f).
ATF3 is a direct downstream target of NRF2 in keratinocytes
upon UVA irradiation
Sequence analysis of the proximal region of the human Atf3
gene promoter revealed the presence of ‘canonical’ antioxidant
response element (ARE)-binding sites located at  3.5 and
 2.9 kb from the transcription start site (Figure 4a). To verify
whether NRF2 binds to these sites, we performed chromatin
immunoprecipitation assays with extracts from human primary
keratinocytes that were either untreated or irradiated with
UVA (Figure 4b). The analysis showed binding of the NRF2
protein to both of the predicted motifs within the promoter
(3.5 and 2.9 kb position) upon UVA irradiation.
CsA and UVA induce ATF3 independently from each other
CsA treatment of primary human keratinocytes slightly induced
ROS formation as assessed by the ROS assay (Figure 3g).
However, this discrete ROS induction had no impact on NRF2
protein expression. In conclusion, CsA treatment did not
induce NRF2 protein expression (Figure 3h). On the other
hand, UVA irradiation of primary human keratinocytes had no
effect on NFATc1 translocation (Supplementary Figure S3
online). In untreated keratinocytes, NFATc1 is located in the
cytoplasm. Upon activation of calcineurin, e.g., by addition of
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Figure 1. Activating transcription factor 3 (ATF3) is a specifically increased AP1 member in squamous cell carcinoma (SCC) of organ transplant recipients
(OTRs). (a) Messenger RNA (mRNA) levels of ATF3 were measured in the epidermis of SCC derived from immuncompetent (IC) and OTR patients (SCC IC and SCC
OTR, respectively). Out of the ‘enlarged’ AP1 family members: the levels of ATF3, ATF2, ATF4, c-Jun, JunB, JunD, c-Fos, FosB, Fra-1, and Fra-2 were measured. Of
the 10 tested genes, only ATF3 showed significant differences in expression between the two groups of patients. (b) The samples were then used for the
measurement of putative ATF3 downstream target expression. GADD153 was upregulated in the SCCs of OTRs. (c) Selection of other putative ATF3 downstream
targets was based on complementary DNA microarray analysis after downregulation or overexpression of ATF3 in primary human keratinocytes (Supplementary
Table S1 online). The analysis showed a significant increase in Vanin-1 (VNN1) and potassium intermediate/small conductance calcium-activated channel,
subfamily N, member 4 (KCNN4) mRNA in cyclosporine-treated patients (SCC OTR) as compared with the IC group of patients (SCC IC). This induction paralleled
the increased levels of ATF3 in the OTR group. *Po0.05; **Po0.01.
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Ca2þ , NFATc1 translocates into the nucleus. This transloca-
tion is inhibited by pretreatment with calcineurin inhibitors
such as CsA. Irradiation of primary human keratinocytes
did not induce the nuclear translocation of NFATc1.
On the other hand, when the cells were first treated
with Ca2þ , thus activating NFATc1, UVA irradiation did not
inhibit the translocation of NFATc1, suggesting a lack of UVA
effect on calcineurin activity (Supplementary Figure S3
online).
DISCUSSION
It is well known that immunosuppressive treatment overall
and particularly treatment with calcineurin inhibitors mark-
edly increases the development of SCC (Dantal et al., 1998). It
is, however, noteworthy that, although the CsA treatment is
systemic, the skin is the organ most affected by SCC (Morath
et al., 2004). On the skin, the predilection sites of SCC are
skewed to the sun-exposed areas (Lindelof et al., 2005). This
indicates that solar irradiation is one of the critical factors
driving SCC development.
ATF3 is a transcription factor with distinct, either oncogenic
or antioncogenic, functions (Thompson et al., 2009). In our
previous study, ATF3 was identified as a CsA-induced onco-
gene that stimulates SCC development (Wu et al., 2010). Our
results demonstrate significantly increased ATF3 mRNA levels
in the group of SCCs that were derived from OTRs.
Interestingly, ATF3 was the only member of the ‘enlarged’
AP-1 family that was induced upon CsA treatment in clinical
samples. Further analysis suggested a biological relevance of
the increase in ATF3 expression. As this is a transcription
factor, it may influence expression of several other genes, thus
having an impact on the cell phenotype and the process
of carcinogenesis. The analysis of our clinical samples
suggests a biological relevance for this recently described
role of ATF3 with isolated upregulation of ATF3 and of its
putative downstream targets such as GADD153, Vanin-1, and
KCNN1.
The previously described mechanism of activation of ATF3
involved NFATc1 inhibition. This proposed mechanism pro-
vides an explanation for the general increase of SCC devel-
opment in OTRs; however, it does not explain the particular
increase of SCC in the sun-exposed areas of skin in OTRs. UV
radiation was recently recognized as a carcinogen along with
X-rays and other hitherto recognized carcinogens (IARC,
2012). UVB is known more for its direct effect on DNA (de
Gruijl, 2002). UVA recently gained more attention for its
indirect effects by oxidation and is of importance mainly
because of its relative abundance in ambient sun light. Recent
work on azathioprine as well as other photosensitizing drugs
(Hofbauer et al., 2012) shows the relevance of drug-induced
photosensitization to UVA in SCC formation in the long run.
Here we show that low-level UVA radiation was similarly
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Figure 2. Activating transcription factor 3 (ATF3) expression is potentiated by cyclosporine A (CsA) and UVA treatment. Primary human keratinocytes
were treated with increasing CsA concentrations for 6 hours. After this time period, the cells were homogenized and the expression of ATF3 was measured at
the (a) messenger RNA (mRNA) and (b) protein level. Primary human keratinocytes were exposed to UVA radiation at 5 and 25 J cm2. Six hours after irradiation,
cells were homogenized and ATF3 expression was measured at the (c) mRNA and (d) protein level. The results showed a significant dose-dependent increase in
ATF3 expression after UVA irradiation. (e) Combined low-level CsA and UVA treatment potentiated ATF3 expression in HKCs at the mRNA and (f) protein level.
The influence of combined CsA and UVA treatment was also measured in fresh-skin organ cultures. The abdominal skin obtained from healthy donors was
incubated in semisolid culture. The skin was pretreated with CsA for 12 hours and then irradiated with UVA at the dose of 10 J cm2. Six hours following irradiation,
the epidermis was separated from the underlying dermis by a brief heat treatment (Kolev et al., 2008). The epidermis was then homogenized and the expression of
ATF3 was measured at both the (g) mRNA and (h) protein level (the ATF3 lines were not originally run next to each other and have been juxtaposed in the figure).
The combined low-level CsA and UVA treatment significantly increased ATF3 expression in the epidermis. *Po0.05; **Po0.01; ***Po0.001. Rel., relative.
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potent in inducing ATF3 as compared with CsA treatment.
Interestingly, when the CsA treatment was combined with
UVA irradiation, ATF3 expression was markedly potentiated.
UVA exposure induces ATF3 expression independently of the
calcineurin–NFATc1 pathway. The UVA radiation levels that
were potent in the induction of ATF3 expression did not
inhibit, nor did they activate, the nuclear translocation of
NFATc1. It is known, however, that UVA strongly induces
formation of ROS (de Gruijl, 2002). We found that the UVA-
mediated induction of ATF3 expression depends on ROS
formation, and could be quenched by a-tocopherol and
b-carotene. As UVB does not induce ROS formation to such
an extent as UVA, our findings may also provide an explana-
tion for only slight induction of ATF3 mRNA observed and for
the lack of ATF3 protein expression after UVB irradiation.
ATF3 gene expression has been shown to be under direct
control of NRF2 in other cells such as monocytes or astrocytes
(Hoetzenecker et al., 2012). We found that NRF2 served as a
link between UVA-mediated induction of ROS formation and
ATF3 expression. Upon UVA irradiation and ROS formation,
NRF2 protein is activated in the cultured primary keratino-
cytes as well as in the epidermis of normal skin, which leads
to binding of NRF2 to the two predicted antioxidant response
element motifs in the ATF3 gene promoter and induces ATF3
expression.
Besides the previously described calcineurin–NFATc1
inhibition–mediated induction of ATF3 expression, we
demonstrate here an independent mechanism of ATF3 expres-
sion, which may be of biological relevance in the process of
cutaneous carcinogenesis. It is important to mention that these
two pathways act independently from each other. Although
CsA treatment slightly induced oxidative stress in the cell, this
effect was too low to stabilize NRF2; however, the UVA
radiation doses that induce ATF3 expression do not interfere
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Figure 3. UVA induces activating transcription factor 3 (ATF3) expression
through reactive oxygen species (ROS)-mediated activation of nuclear factor
erythroid 2–related factor 2 (NRF2). (a) a-Tocopherol and b-carotene are
potent ROS scavengers. HKCs were pretreated with a-tocopherol or b-carotene
for 1 hour before UVA exposure. The cells were then irradiated with low-dose
UVA (1 J cm2) followed by ROS measurement assay. b-Carotene acts as a
more potent scavenger of ROS as compared with a-tocopherol. (b)
Pretreatment for 1 hour of cultured human keratinocyte with a-tocopherol or b-
carotene reduces UVA-mediated induction of ATF3 expression. After the
pretreatment, cells were irradiated and left in the culture for another 6 hours,
and then harvested (the ATF3 lines were not originally run next to each other
and have been juxtaposed in the figure). (c) UVA-mediated induction of ATF3
expression in normal human skin was reduced by b-carotene treatment.
Normal human skin was pretreated with b-carotene 1 hour before exposure to
UVA. Six hours after irradiation, the epidermis was peeled from the dermis and
homogenized for ATF3 expression. Real-time PCR showed significantly
reduced induction of UVA-mediated ATF3 expression in b-carotene pretreated
skin. (d) Normal skin pretreated with b-carotene and exposed to UVA showed
significantly decreased protein levels of ATF3. UVA irradiation increased the
protein level of NRF2, which was reduced by pretreatment with b-carotene. (e)
HKCs were treated with NRF2-specific small interfering RNA (siRNA) (siNRF2)
and then exposed to 5 J cm2 of UVA. The control cells showed increased
protein levels of NRF2 and ATF3. siRNA-mediated inhibition of NRF2 reduced
the UVA-mediated induction of ATF3 expression. (f) Cultured cells were
pretreated with NRF2-specific or control siRNA (siNRF2 and siCtrl,
respectively) 6 hours before treatment with the known NRF2 stabilizer—tBHQ.
Six hours after the tBHQ treatment, cells were homogenized for western blot.
The analysis showed induction of ATF3 by tBHQ treatment following the
induction of NRF2. siRNA-mediated inhibition of NRF2 expression inhibited
the tBHQ-mediated increase in ATF3 expression. (g) The cyclosporine A (CsA)-
and UVA-mediated pathways of ATF3 induction act independently of each
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(CM-H2DCFDA) was used to assess the ROS levels. The UVA-irradiated cells
(green curve) showed high levels of ROS, and pretreatment with CsA had no
influence on ROS levels (blue curve). CsA treatment of primary keratinocytes
induced low levels of ROS formation in the cells (orange curve). (h) Cultured
HKCs were treated with either 5mM CsA or UVA at 5 J cm2. Six hours after
treatment, cells were homogenized, and ATF3 and NRF2 levels were measured
by western blot. UVA irradiation stabilized NRF2 protein levels and induced
ATF3 formation. CsA treatment had no influence on NRF2 protein levels;
however, it induced ATF3 expression. *Po0.05; **Po0.01; ***Po0.001.
tBHQ, tert-butylhydroquinone.
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with the NFATc1 activity. A schema representing our pro-
posed mechanism of ATF3 induction by combined CsA
treatment and UVA irradiation is summarized in Figure 5. In
summary, our data suggest a potentiation of ATF3 by CsA and
UVA as a mechanism for the greatly increased incidence of
SCC in OTRs with a predilection for sun-damaged skin.
Here we show the importance of UVA irradiation in the skin
carcinogenesis of CsA-treated patients. This study suggests a
greater influence of UVA than of UVB in this process. The
verification of this hypothesis in an animal model by compar-
ing UVA with UVB influence in CsA-treated mice on skin
cancer development remains to be done.
MATERIALS AND METHODS
Skin SCC samples
The cutaneous SCC (immuncompetent: n¼ 19, OTR: n¼ 12) samples
were obtained at the Department of Dermatology of the University
Hospital in Zurich, Switzerland, from clinical biopsies. All OTR
patients were on CsA treatment for at least 5 years at the time of
excision. Parts not needed for histological diagnosis were further
processed. Normal skin was obtained from healthy donors under-
going abdominal reconstructive surgery. Institutional board approval
as well as written informed patient consent were obtained for all the
analyses.
Cell and organ cultures, plasmids, viruses, and siRNA
Conditions for generation and culturing of primary human keratino-
cytes were reported previously (Dziunycz et al., 2010). Infection with
retroviruses expressing ATF3 together with corresponding controls was
described previously (Wu et al., 2010). CsA (Novartis), a-tocopherol,
and tert-butylhydroquinone (Sigma, Bucks, Switzerland) were dissolved
in ethanol and stored in a stock solution at  20 1C. b-Carotene
(Sigma) was always freshly dissolved in chloroform before the experi-
ments. For knockdown experiments, cells were transfected as described
(Restivo et al., 2011) with siRNA for the human NRF2 (Invitrogen, Zug,
Switzerland) and for ATF3 (GeneGlobe, Qiagen, Basel, Switzerland)
in parallel with corresponding scrambled siRNA controls and
analyzed 12 and 72 hours, respectively, after transfection.
Untreated keratinocytes
ARE motifs
UVA-irradiated keratinocytes
***
*** ***
***
Positive ctrl – 3.5k bp – 2.9k bp
70
60
50
20
0
10
40
30
Positive ctrl – 3.5k bp – 2.9k bp
70
– 3.5k bp – 2.9k bp
ATF3
TSS
60
50
20
0
10
40
30
IgG
NRF2 Ab
IgG
NRF2 Ab
Figure 4. UVA irradiation induced binding of endogenous nuclear factor erythroid 2–related factor 2 (NRF2) to the activating transcription factor 3 (ATF3) locus
within specific regions of chromatin organization. (a) Schematic illustration of chromatin immunoprecipitation (ChIP) results: TSS, transcription starting site;
ARE-binding motifs are represented by the red bars. (b) ChIP assay was performed on untreated (left panel) and on UVA-irradiated human keratinocytes. The cell
extracts were processed for ChIP assays using an antibody specific for NRF2, utilizing nonimmune IgGs as control (ctrl). PCR amplification of the two regions of the
human ATF3 promoter encompassed the following ARE-binding sites:  3.5 k bp: 50-TGACACAGC-30;  2.9 k bp: 50-TGAGTGAGA-30. The results are
representative of two independent experiments. The relative amount of precipitated DNA, expressed in arbitrary units, was calculated after normalization for total
input chromatin, according to the following formula: % total¼2deltaCt 5, where deltaCt¼Ct (input)Ct (immunoprecipitation). Ct, cycle threshold.
***Po0.001. ARE, antioxidant response element.
Cyclosporin UVA
Calcineurin ATF3 Nrf2
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Figure 5. Schema representing the proposed mechanism of synergistic
UVA- and cyclosporine A-mediated activating transcription factor 3 (ATF3)
induction. Cyclosporine treatment through inhibition of calcineurin–NFAT
signaling enhances expression of ATF3, a negative regulator of p53 gene
transcription. The resulting downmodulation of p35 levels inhibits cancer cell
senescence and can explain, in part, increased predisposition to cancer
development. On the other hand, UVA radiation increases the reactive oxygen
species (ROS) formation in the sun-exposed keratinocytes. This ROS formation
leads to the activation of nuclear factor erythroid 2–related factor 2 (NRF2),
which is a transcription factor that binds to ATF3 promoter and induces its
expression. Thus, sun-exposed skin of cyclosporine-treated patients is
particularly predisposed to skin cancer development. The proposed
mechanism may explain this often observed clinical phenomena among organ
transplant recipients.
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UV irradiation
The UV irradiation experiments were performed as described
previously (Dziunycz et al., 2010).
Reverse transcription and quantitative real-time PCR
The reverse transcription and quantitative real-time PCR was per-
formed as described previously (Kosmidis et al., 2010). The primer
sequence is listed in the Supplementary Data online.
Western blot and antibodies
Western blotting was performed as described previously (Restivo et al.,
2011). The following antibodies were used: actin (sc-1616), NRF2
(sc-365949), ATF3 (sc-188), and NFATc1 (sc-7294; Santa Cruz,
Heidelberg, Germany).
Chromatin immunoprecipitation assay
In all, 80% confluent primary human keratinocytes were left
untreated or were irradiated with UVA at 5 J cm 2. One hour
later, cells were cross-linked with 37% formaldehyde in a
final concentration of 1% for 10 minutes at room temperature
followed by the addition of glycine (final concentration 125 mM).
After cross-linking, cells were washed twice with 10 ml phos-
phate-buffered saline with protease inhibitor. Cell pellets were
processed for chromatin immunoprecipitation assays using the
Magna ChIP A/G Kit (Millipore, Zug, Switzerland) following the
manufacturer’s protocol. The anti-NRF2 antibody (Santa Cruz,
sc365949) in parallel with affinity-purified nonimmune IgGs was
used. Primers used for real-time PCR are listed in the Supplementary
Data online.
Flow cytometry analysis of ROS formation
ROS formation was measured by flow cytometry. HKCs were cultured
up to 70% of confluence. Before UVA exposure they were incubated
for 20 minutes with CM-H2DCFDA dye (Molecular Probes, Eugene,
OR). Cells were then irradiated with UVA at 0.1 J cm 2, after which
they were immediately trypsinized and analyzed. Measurements were
performed on a FACSCanto device (BD Biosciences, Allschwil,
Switzerland) as described (O’Donovan et al., 2005). Data were
analyzed with FlowJo software (Ashland, OR).
Statistics
All the experiments were performed at least three times. The graphs
represent the compilation of the results. For western blot analysis,
representative results have been chosen. All statistical evaluations
were carried out using GraphPad Prism 5.0 (GraphPad, La Jolla, CA).
The analyses were two-tailed Student’s t-test or analysis of variance.
All real-time reverse transcriptase–PCR samples were tested in
triplicates, and error bars represent one standard deviation. P-values
of o0.05 were considered significant.
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